4SCAR-T
/ SZGIMI
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
September 09, 2025
Intervention of Bladder Cancer by CAR-T
(clinicaltrials.gov)
- P1/2 | N=20 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Unknown status ➔ Recruiting | Trial completion date: Dec 2020 ➔ Dec 2029 | Trial primary completion date: Dec 2019 ➔ Dec 2028
Enrollment open • Trial completion date • Trial primary completion date • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer
January 09, 2023
Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma.
(PubMed, Mol Cancer)
- P1 | "Both single and combined infusions of GD2-specific 4SCAR-T cells in targeting GBM were safe and well tolerated, with no severe adverse events. In addition, GD2-specific 4SCAR-T cells partially mediate antigen loss and activate immune responses in the tumor microenvironment. Validation of our findings in a larger prospective trial is warranted."
CAR T-Cell Therapy • Journal • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
July 15, 2022
CAR-T Cells Targeting Autoimmune Diseases
(clinicaltrials.gov)
- P1/2 | N=30 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute
CAR T-Cell Therapy • New P1/2 trial • Immunology
1 to 3
Of
3
Go to page
1